Michigan Administrative Code › Department - Licensing and Regulatory Affairs › Bureau of Community and Health Systems › Substance Use Disorder Programs › Substance Use Disorder Programs › Part 4 - SPECIAL REQUIREMENTS BY SERVICE CATEGORIES › Section R. 325.1383 - Methadone program requirements

Current through Vol. 24-12, July 15, 2024
Rule 1383.
(1)
					 Methadone program services must be based on a documented assessment of the
					 recipient's needs and a subsequent agreement between the recipient and the
					 provider about the services to be offered.
(2) An applicant or licensee shall employ a
					 licensed counselor, LMSW, licensed psychologist, or LMFT.
(3) A licensee shall establish, maintain, and
					 publicly post hours for counseling services.
(4) A licensed counselor, limited licensed
					 counselor under the supervision of a licensed counselor, LMSW, limited LMSW
					 under the supervision of a LMSW, licensed psychologist, limited licensed
					 psychologist under the supervision of a licensed psychologist, temporary
					 limited licensed psychologist under the supervision of a licensed psychologist,
					 post-doctoral education limited licensed psychologist under the supervision of
					 a licensed psychologist, LMFT, limited LMFT under the supervision of an LMFT,
					 certified counselor, or limited certified counselor under the supervision of a
					 licensed or certified individual listed in these rules must be available to
					 provide counseling services as required in a recipient service plan.
(5) A licensee shall ensure that any licensed
					 counselor, limited licensed counselor, LMSW, limited LMSW, licensed
					 psychologist, limited licensed psychologist, temporary limited licensed
					 psychologist, post-doctoral education limited licensed psychologist, LMFT,
					 limited LMFT, or certified counselor is not responsible for more than 65
					 recipients.
(6) A licensee shall
					 ensure that a limited certified counselor is not responsible for more than 32
					 recipients.
(7) An applicant or
					 licensee shall employ a medical director. If the medical director is not onsite
					 during all hours of operation, then the licensee shall establish specific
					 timeframes in which the medical director shall be onsite.
(8) During all hours that recipients are
					 receiving medication, a licensee shall have onsite a physician, physician's
					 assistant, advanced practice registered nurse, registered professional nurse,
					 or licensed practical nurse under the supervision of a registered professional
					 nurse or physician.
(9) The medical
					 director, physician, physician's assistant, or advanced practice registered
					 nurse shall document that the recipient has been diagnosed with a substance use
					 disorder. The recipient shall be diagnosed with a substance use disorder and
					 have documented opioid use disorder for 1 year or more.
(10) Before any medications are prescribed,
					 the medical director, a physician, physician's assistant, or advanced practice
					 registered nurse shall complete and document the medical and drug history and
					 physical examination of the recipient. In addition, any modification to
					 medications or course of treatment must be documented in the recipient record
					 and ordered by a physician, physician's assistant, or advanced practice
					 registered nurse.
(11) Within 30,
					 60, and 90 days of treatment, and not less than every 90 days thereafter, the
					 medical director, a physician, physician's assistant, or advanced practice
					 registered nurse shall meet with the recipient to review the recipient's
					 service plan, including a review of the counseling services progress notes and
					 drug tests, and document the medical necessity for continued treatment in the
					 program and any recommended adjustments to the service plan.
(12) A licensee shall comply with all
					 requirements set forth in 42
					 CFR 8.
(13) The licensee shall document in the
					 service plan the phase the recipient is in, including short-term withdrawal
					 management, long-term withdrawal management, or maintenance.
(14) A licensee shall have a policy and
					 procedure for labeling take-home medications that includes all of the
					 following:
(a) The name of the
					 medication.
(b) The program's name,
					 address, and phone number.
(c)
					 Recipient name or code number.
(d)
					 Medical director's name.
(e)
					 Directions for use.
(f) Date to be
					 used by.
(g) A cautionary statement
					 that the drug should be kept out of the reach of children.